BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 21 November 2013, at 4.00 p.m. Biotie's loan obligations to Tekes reduced by EUR 2.8 million The Finnish Funding Agency for Technology and Innovation (Tekes) has, based on an application from Biotie, informed the Company that it has decided to forgive certain capital loans relating to Biotie's carbohydrate and cancer glycosylation projects that were discontinued in 2005 and an R&D loan relating to Biotie's Integrin project that was discontinued in 2010. Biotie's justification for the application was that the Tekes funded R&D projects did not lead to commercially profitable business. The loan forgiveness will reduce the group's non-current financial liabilities on the consolidated statement of financial position by EUR 2.8 million and increase financial income on the consolidated statement of comprehensive income by EUR 2.8 million in the full year financial statements for 2013. In addition, all accrued interest relating to these loans is also forgiven. This will reduce other non-current liabilities on the consolidated statement of financial positions by EUR 0.4 million and increase financial income on the consolidated statement of comprehensive income by EUR 0.4 million in the full year financial statements for 2013. As at 31 December 2012 the Company's loan obligations to Tekes were EUR 17.4 million as capital loans and EUR 4.4 million as R&D loans. In Turku, 21 November 2013 Biotie Therapies Corp. Timo Veromaa, President and CEO For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com Distribution: NASDAQ OMX Helsinki Ltd Main Media www.biotie.com ABOUT BIOTIE Biotie is a specialized drug development company focused primarily on products for neurodegenerative and psychiatric disorders. For the past years, Biotie has successfully operated a strategy built around search, profile and partner. This has delivered Selincro (nalmefene) for alcohol dependency, which received European marketing authorization in February 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S, and tozadenant, a novel A2a antagonist which is transitioning into Phase 3 development for Parkinson's disease in collaboration with UCB Pharma S.A.. Biotie also has exclusive rights through an option to acquire Neurelis Inc., which includes NRL-1, an intranasal formulation of diazepam for epileptic seizure management. Biotie plans to seek further opportunities of this kind to generate a strong portfolio of products. Biotie's shares are listed on NASDAQ OMX Helsinki. [HUG#1744931]